The ABTECT clinical program included the randomized, double-blind, placebo-controlled phase 3 ABTECT-1 and ABTECT-2 trials.

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

Shares of Abivax (NASDAQ:ABVX) surged more than 400% in Paris trading on Wednesday after the French biotech company announced that its experimental drug obefazimod met key goals in two pivotal Phase 3 ...

After a long, cash-strapped journey, French biotech Abivax has presented top-line data from the twin phase 3 trials of its lead ulcerative colitis candidate.  | After a long, cash-strapped journey, ...

An experimental oral treatment from Abivax helped ease symptoms in patients with ulcerative colitis, a major win for the ...

An oral neutrophil modulator appeared safe and demonstrated signals of efficacy in patients with moderate to severe ...

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is often perceived as a condition ...

Specific protein signatures could predict a future diagnosis of Crohn disease and ulcerative colitis, potentially enabling earlier intervention and improving patient outcomes.

It’s important to know the difference between colitis and ulcerative colitis because treatment for these conditions can differ.

It’s important to know the difference between colitis and ulcerative colitis because treatment for these conditions can differ.

It is estimated that more than 5 million people worldwide suffer from ulcerative colitis, a chronic inflammation of the colon that often progresses in stages whose causes have not yet been fully ...

A new meta-analysis reveals significant sex-based differences in how ulcerative colitis (UC) is managed, with females experiencing higher hospitalization rates and receiving fewer immunomodulator ...